

ONWARD Adds New Brain-Spine Interface and Parkinson's Disease IP to License Agreements

ONWARD obtains rights to breakthrough innovations in Brain-Spine Interface and Parkinson's disease

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland—March 28, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announces two new innovations have been added to its portfolio of license agreements with the Swiss Federal Institute of Technology Lausanne (EPFL), one of the world's preeminent neuroscience research institutions, and Lausanne University Hospital (CHUV), ranked among the top 10 hospitals in the world.

ONWARD has been granted the rights to leverage EPFL and CHUV intellectual property to develop and commercialize the following therapies currently under evaluation in clinical feasibility studies conducted by [.NeuroRestore](#), a leading center for neurorestorative therapies:

- Restoring mobility (standing, walking, etc.) and upper limb function using a wireless brain-spine interface (BSI) that captures brain signals recorded by a brain implant to trigger spinal cord stimulation, restoring voluntary control over paralyzed arms and legs. This therapy is being studied for clinical feasibility in the [STIMO-BSI](#) Trial: Brain-controlled Spinal Cord Stimulation in Patients with Spinal Cord Injury); and
- Alleviating gait disorders (freezing of gait, etc.) in people with Parkinson's disease by stimulating the spinal cord, building on insights gained in the [STIMO](#) Trial that showed programmed, targeted stimulation of the spinal cord could restore the ability to stand and walk even after complete spinal cord injury. This therapy is being studied for clinical feasibility in the [STIMO-Park](#) Trial: Study on Feasibility of Targeted Epidural Spinal Stimulation to Improve Mobility in Patients With Parkinson's Disease).

There are 650,000 people in the US and Europe with spinal cord injury who may gain additional benefit from brain-spine interface technology when used in combination with ONWARD's ARC Therapy, allowing them to potentially stand and walk again. Nearly 1,000,000 people in the US and Europe have gait disorders due to Parkinson's disease; spinal cord stimulation via ARC Therapy may sustain their ability to walk and maintain independence and quality of life despite their neurodegenerative condition.

"These new rights add to ONWARD's impressive portfolio of patents and exclusive licenses with the world's leading neuroscience research laboratories", said Dave Marver, CEO of ONWARD. "Our work with EPFL and CHUV on therapies leveraging a brain-spine interface may help a broader group of people with spinal cord injury recover and optimize mobility and upper limb function. We are also eager to further explore and potentially commercialize therapies that may restore and preserve mobility for people with Parkinson's disease, though our current focus remains serving the SCI community."

To learn more about ONWARD's ARC Therapy and the company's vision to restore movement, independence and health in people with spinal cord injury, please visit [ONWD.com](https://onwd.com).

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy, which can be delivered by implantable (ARC^{IM}) or external (ARC^{EX}) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC^{IM} and ARC^{EX}. The company's first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit [ONWD.com](https://onwd.com). To access our 2022 Financial Calendar, please visit [IR.ONWD.com](https://ir.onwd.com).

For Media Enquiries:

media@onwd.com +44 (0)20 3757 6772

For Investor Enquiries:

investors@onwd.com

For Company Enquiries:

ONWARD – info@onwd.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking

statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.